Cresco Labs (CL, CRLBF) Q1 2025 Earnings – Full Coverage скачать в хорошем качестве

Cresco Labs (CL, CRLBF) Q1 2025 Earnings – Full Coverage

Cresco Labs Inc. (CSE: CL, OTCQX: CRLBF) reported Q1 2025 revenue of $166M, with adjusted gross margin at 49% and adjusted EBITDA of $36M (22% margin). Operating cash flow was $30M, boosting cash reserves to $162M, the highest in three years. Strategic moves include limiting risky wholesale accounts, expanding in Pennsylvania and Ohio, and entering Kentucky’s medical cannabis market. Join CEO Charles Bachtell, CFO Sharon Schuler, and President Greg Butler for insights on cash flow strength and growth! ⏱️ Timestamps (based on transcript): 00:00 – Introduction 00:41 – SVP T.J. Cole: Opening Remarks 01:50 – CEO Charles Bachtell: Business Update 09:12 – CFO Sharon Schuler: Financial Results 13:59 – Q&A Session Begins 14:22 – Pricing Pressure Outlook 31:02 – Closing Remarks 📈 Investment Sentiment: BUY – Strong cash generation and disciplined strategy position Cresco for growth, despite market challenges. 📐 Suggested Allocation: 1–2% of a diversified portfolio, with 5–7% cash for volatility. 📢 Disclaimer: This video includes segments from Cresco Labs’ Q1 2025 earnings call, used for educational purposes under fair use (Section 107, US Copyright Act). No affiliation or endorsement by Cresco Labs is implied. All rights remain with Cresco Labs. For details, visit [https://www.crescolabs.com/investors/](https://www.crescolabs.com/investors/). For inquiries, contact [email protected]. 💬 Comment below: What’s your view on Cresco’s cash flow strategy? 👉 Subscribe for more earnings insights! 👉 Follow us: https://x.com/Fyfull2 👉 More analysis: [Q1 2025 Earnings Playlist]